Latest Evidence in Personalized Antiplatelet Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (Q38012079)

From Wikidata

Jump to navigation Jump to search

scientific article published on April 1, 2012

Language	Label	Description	Also known as
English	Latest Evidence in Personalized Antiplatelet Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention	scientific article published on April 1, 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Latest Evidence in Personalized Antiplatelet Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (English)

1 reference

10.3810/HP.2012.04.976

https://api.crossref.org/works/10.3810/HP.2012.04.976

1 January 2025

acute coronary syndrome

1 reference

based on heuristic

inferred from title

percutaneous coronary intervention

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22615085

1 January 2025

author name string

Sabrina Uhry

1

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Jacques Bessereau

2

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Laurence Camoin-Jau

3

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Franck Paganelli

4

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Laurent Bonello

5

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

language of work or name

0 references

publication date

1 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

April 2012

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22615085

1 January 2025

full work available at URL

http://www.tandfonline.com/doi/pdf/10.3810/hp.2012.04.976

1 reference

10.3810/HP.2012.04.976

https://api.crossref.org/works/10.3810/HP.2012.04.976

1 January 2025

Hospital Practice

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

40

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

104-117

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

The Link Between Vascular Features and Thrombosis

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Molecular and cellular biology of blood coagulation

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Aspirin resistance

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Towards a definition of aspirin resistance: a typological approach

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Platelet activation in myocardial ischemic syndromes

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Terms and conditions: semantic complexity and aspirin resistance

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Effect of ranitidine on the antiplatelet effects of aspirin in healthy human subjects

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Pharmacogenetics of aspirin resistance: a comprehensive systematic review

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Aspirin resistance

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Individual variations of platelet inhibition after loading doses of clopidogrel

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis.

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Measuring antiplatelet drug effects in the laboratory

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Platelet function monitoring in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Structure and stereochemistry of the active metabolite of clopidogrel

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Recent developments in clopidogrel pharmacology and their relation to clinical outcomes

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibati

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score.

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events.

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patien

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platele

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Modifying Clopidogrel Maintenance Doses According to Vasodilator‐Stimulated Phosphoprotein Phosphorylation Index Improves Clinical Outcome in Patients With Clopidogrel Resistance

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Calcium-channel blockers reduce the antiplatelet effect of clopidogrel

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

The association of cigarette smoking with enhanced platelet inhibition by clopidogrel

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Genetic determinants of response to clopidogrel and cardiovascular events

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Cytochrome p-450 polymorphisms and response to clopidogrel

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

The difference between clopidogrel responsiveness and posttreatment platelet reactivity

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Ca

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome.

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE st

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Effect of Paraoxonase-1 Polymorphism on Clinical Outcomes in Patients Treated With Clopidogrel After an Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Paraoxonase-1 and clopidogrel efficacy

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

1 reference

https://api.crossref.org/works/10.3810/HP.2012.04.976

21 January 2018

Are we mortgaging the medical profession?

2

1 reference

10.3810/HP.2012.04.976

https://api.crossref.org/works/10.3810/HP.2012.04.976

1 January 2025

Pathology of transluminal balloon angioplasty used in the treatment of coronary heart disease

3

1 reference

10.3810/HP.2012.04.976

https://api.crossref.org/works/10.3810/HP.2012.04.976

1 January 2025

Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome

39

1 reference

10.3810/HP.2012.04.976

https://api.crossref.org/works/10.3810/HP.2012.04.976

1 January 2025

ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome

40

1 reference

10.3810/HP.2012.04.976

https://api.crossref.org/works/10.3810/HP.2012.04.976

1 January 2025

Impact of P-glycoprotein on clopidogrel absorption

68

1 reference

10.3810/HP.2012.04.976

https://api.crossref.org/works/10.3810/HP.2012.04.976

1 January 2025

Platelet function in clopidogrel-treated patients with acute coronary syndrome

72

1 reference

10.3810/HP.2012.04.976

https://api.crossref.org/works/10.3810/HP.2012.04.976

1 January 2025

Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects

73

1 reference

10.3810/HP.2012.04.976

https://api.crossref.org/works/10.3810/HP.2012.04.976

1 January 2025

Paraoxonase-1 is a major determinant of clopidogrel efficacy

83

1 reference

10.3810/HP.2012.04.976

https://api.crossref.org/works/10.3810/HP.2012.04.976

1 January 2025

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting

84

1 reference

10.3810/HP.2012.04.976

https://api.crossref.org/works/10.3810/HP.2012.04.976

1 January 2025

An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial

102

1 reference

10.3810/HP.2012.04.976

https://api.crossref.org/works/10.3810/HP.2012.04.976

1 January 2025

Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopi

104

1 reference

10.3810/HP.2012.04.976

https://api.crossref.org/works/10.3810/HP.2012.04.976

1 January 2025

Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?

111

1 reference

10.3810/HP.2012.04.976

https://api.crossref.org/works/10.3810/HP.2012.04.976

1 January 2025

High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes

114

1 reference

10.3810/HP.2012.04.976

https://api.crossref.org/works/10.3810/HP.2012.04.976

1 January 2025

Identifiers

10.3810/HP.2012.04.976

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38012079&oldid=2293818609"